1. Introduction {#sec1}
===============

Nasu-Hakola disease (NHD, OMIM 221770), also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, is a rare autosomal recessive disease characterized by a combination of progressive young-onset dementia and multifocal bone cysts ([@bib8]). In most Nasu-Hakola patients, the clinical course of the disease can be divided into 4 stages: (1) the latent stage with normal early development; (2) the osseous stage beginning at the third decade of life, characterized by pain and swelling in ankles and feet followed by frequent bone fractures; (3) the early neuropsychiatric stage occurring at the fourth decade of life, presenting with a frontal lobe syndrome including euphoria and social disinhibition; and (4) the late neuropsychiatric stage, characterized by profound dementia, loss of mobility, and death usually by age of 50 years ([@bib6]). NHD is caused by mutations in 1 of 2 genes: TYRO protein tyrosine kinase--binding protein (*TYROBP*) on chromosome 19q13.1 and triggering receptor expressed on myeloid cells 2 (*TREM2*) on chromosome 6p21.1.

Recently, cases with homozygous mutations in *TREM2* have been described to present atypical phenotypes resembling behavioral variant frontotemporal dementia (bvFTD) and lacking stage (2) of the clinical picture described previously ([@bib1; @bib2; @bib4]).

At present, 14 different mutations have been identified in *TREM2* including nonsense, missense, small deletions, and splice site homozygous mutations ([@bib2]). Here, we report the first *TREM2* compound heterozygous mutation identified in a Turkish family presenting with an FTD-like phenotype.

2. Methods {#sec2}
==========

2.1. Patients {#sec2.1}
-------------

The proband is currently being followed in the outpatient clinic of the Behavioral Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University. She was hospitalized in 2012 for a detailed neurologic workup. Written informed consent was obtained from all family members, and this study was approved by the ethical committee of the Istanbul University.

2.2. Genetic analysis {#sec2.2}
---------------------

DNA was extracted from blood samples, according to standard procedures. For the proband, all coding exons of *TREM2* were amplified by polymerase chain reaction (PCR) using Roche FastStart PCR Master Mix (Roche Diagnostics Corp). The PCR products were sequenced using the same forward and reverse primers (primers available on request) with Applied Biosystems BigDye terminator version 3.1 sequencing chemistry and run on an ABI3730XL genetic analyzer as per the manufacturer\'s instructions (Applied Biosystems). The sequences were analyzed using Sequencher software, version 4.2 (Gene Codes). For family members, only exon 2 of *TREM2* was tested.

3. Results {#sec3}
==========

3.1. Case report {#sec3.1}
----------------

The proband is a 41-year-old female who presented with a 1-year history of a change in personality. She had become increasingly apathetic, and her husband reported that she had become less empathic toward close family and friends, unexpectedly leaving her husband and their child in the United States to move back to her parents\' house in Turkey. At this time, her mother noticed that she had started to become more perseverative in her behavior and developing a change in food preference, eating more junk food. She also started to have mild word-finding difficulties. She had been previously fit and well apart from having had 2 previous generalized tonic-clonic seizures (one 4 years earlier and one 2 years earlier).

Her parents were originally from the same city (Erzincan) with a population of about 225,000 inhabitants, located in the eastern part of Turkey and were both clinically healthy. She had 2 siblings, a brother who was well and a sister who had also developed progressive cognitive impairment and behavioral problems with generalized tonic-clonic seizures starting in her 30s ([Fig. 1](#fig1){ref-type="fig"}).

She scored 44 on the Addenbrooke\'s cognitive examination (range 0--100, higher scores indicating better performance) and 28 on the frontal behavioral inventory (range 0--72, higher scores indicating worse behavioral symptoms; disinhibition subscore 11, negative behavior subscale score 17). Formal neuropsychometry testing revealed deficits in executive function, particularly abstract thinking, planning, and inhibition. There was also evidence of language dysfunction with nonfluent speech, anomia, and phonemic paraphasias although comprehension and repetition were normal. Other cognitive domains were relatively intact, and both neurologic and general systemic examinations were normal.

Blood tests were normal including serum calcium, phosphate, and parathyroid hormone. Cerebrospinal fluid analysis revealed a mild pleocytosis (10 lymphocytes per cubic millimeter) and mildly increased protein (54 mg/dL) with positive unmatched oligoclonal bands. Electroencephalography was normal. Magnetic resonance imaging of the brain showed atrophy mainly located in the frontal, lateral temporal, and parietal cortices and also the caudate nuclei with marked thinning of the corpus callosum and enlargement of the ventricular system. On T2 and fluid-attenuated inversion recovery imaging, there was evidence of diffuse hyperintensities in the periventricular, frontal, and occipitoparietal white matter ([Fig. 2](#fig2){ref-type="fig"}). There were also symmetrical hypointense lesions bilaterally in the globus pallidus on T1, T2, and fluid-attenuated inversion recovery imaging ([Fig. 3](#fig3){ref-type="fig"}). These were considered to be calcification because computed tomography of the brain revealed marked hyperdense lesions ([Fig. 4](#fig4){ref-type="fig"}) in the same areas. Further tests included a skeletal X-ray survey, which showed no bone cysts.

3.2. Genetic analysis {#sec3.2}
---------------------

In the proband, PCR and direct sequencing analysis of the 5 exons and exon-intron boundaries of *TREM2* identified 2 different missense heterozygous mutations: c.113A\>G, p.Y38C and c.257A\>T, p.D86V in exon 2 (NM_018965.3).

To determine if the patient was a compound heterozygote, we sequenced exon 2 in the parents. The father carried the p.Y38C heterozygous variant and the mother carried the p.D86V also heterozygous; thus, the proband carries a compound heterozygous mutation: c.\[113A\>G\];\[257A\>T\]; p.\[(Y38C)\];\[(D86V)\].

To assess segregation of the mutation with the disease, we sequenced 2 siblings, 1 affected and 1 unaffected. The compound heterozygous mutation segregated with the disease, being present in the affected siblings and absent in the unaffected, who carried only one of the variants (p.Y38C) ([Fig. 1](#fig1){ref-type="fig"}).

None of these variants are reported on large genetic databases (dbSNP version 137, 1000Genomes Project or Exome Variant Server, NHLBI GO Exome Sequencing Project, Seattle, WA, <http://evs.gs.washington.edu/EVS/>, accessed on May, 2013), but we have previously reported both changes in the Turkish population. Homozygosity for the p.Y38C mutation was found in the only affected subject from family 2, and p.D86V was found in heterozygosity in a healthy control individual from 76 Turkish controls screened for *TREM2* exon 2 mutations in our previous study ([@bib4]).

4. Discussion {#sec4}
=============

Both homozygous and compound heterozygous mutations in *TYROBP* are known to cause NHD ([@bib7]). Homozygous mutations in *TREM2* also cause NHD. More recently, we and others have found homozygous mutations in this gene to be associated with bvFTD-like phenotype without any associated bone involvement ([@bib1; @bib2; @bib4]). Here, we report the first compound heterozygous mutation in *TREM2*, which was found to be associated with FTD phenotype in a Turkish family.

The proband in the family here described was identified because she presented a clinical picture similar to the 3 previous bvFTD-like cases with homozygous *TREM2* mutations we reported before ([@bib4]). In addition to these 3 Turkish cases, 2 other families were also reported to carry homozygous mutations in *TREM2*, presenting with a bvFTD-like phenotype without bone cysts. [@bib1] described a Lebanese family presenting with a young-onset dementia without bone cysts where 3 affected subjects carried a deletion (c.40+3delAGG) in the 5′ consensus donor splice site in intron 1 of *TREM2*. These affected individuals developed personality and behavioral changes at the age of 30--35 years, culminating in severe dementia. Brain magnetic resonance imaging showed cortical atrophy with periventricular white matter disease ([@bib1]). More recently, [@bib2] reported a novel homozygous nonsense mutation (p.W198X) in a Colombian family with an autosomal recessive pattern of inheritance of FTD, also without bone cysts. These patients started to develop behavioral and personality changes around the age of 45--50 years. Similar to this case and the previously described Turkish cases, the affected siblings in the Colombian family also developed seizures ([Table 1](#tbl1){ref-type="table"}).

Dementia in the form of an early-onset personality change, resembling bvFTD, seems to be the most common feature of all these reported cases, most often associated with seizures and characteristic imaging findings, such as callosal atrophy and diffuse white matter lucency. Familial FTD accounts for \>40% of all cases, and to date, several genetic causes of the phenotype have been described. However, all the 7 genes with mutations causing familial FTD (i.e., *MAPT*, *GRN*, *C9ORF72*, *VCP*, *CHMP2B*, *TARDBP*, and *FUS*) are dominantly inherited. *TREM2* mutations appear to be the first addition to this list as a recessively inherited genetic cause. We suggest that a family history of consanguinity along with somewhat atypical features, such as seizures and callosal atrophy, in a patient presenting with a bvFTD phenotype should prompt the diagnostician to look for a likely *TREM2* homozygous or compound heterozygous mutation. In the same line of reasoning, this genetic cause should be included in the differential diagnosis of young-onset dementia with seizures. Hitherto, adult neuronal ceroid lipofuscinosis (also known as Kufs disease) remains the prototype of this presentation.

The precise molecular and cellular mechanisms underlying the pathogenesis of these diseases are not yet known. There seems to be no correlation between the type of mutation and the associated phenotype because nonsense, splice site, and missense mutations have now been associated with FTD cases. TREM2 is a membrane protein that forms a receptor-signaling complex with TYROBP, triggering the activation of the immune response, differentiation of dendritic cells and osteoclasts, and phagocytosis in microglia. It is interesting to note that a heterozygous variant (p.R47H) in *TREM2* has recently been shown to increase the risk for Alzheimer\'s disease ([@bib3; @bib5]). This suggests that TREM2 is part of a functional network involved in different neurodegenerative dementias (FTD, Alzheimer\'s disease, and Nasu-Hakola), but besides the fact that homozygous mutations cause an early-onset and more severe disease, whereas heterozygous variants increase the risk for a late-onset disorder, it is not possible to establish a specific correlation between genotype and phenotype.
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![Pedigree of the family where the compound heterozygous mutation p.\[(Y38C)\];\[(D86V)\] in *TREM2* was found. The arrowhead indicates the proband. Black filled symbols represent affected subjects with dementia. White symbols represent unaffected family members. The *TREM2* variants found are represented below each individual showing segregation of the compound heterozygous mutation with the disease.](gr1){#fig1}

![Magnetic resonance imaging of the proband. (A) Transverse T1-weighted image shows atrophy of the frontoparietal cortices. (B) Transverse fluid-attenuated inversion recovery image demonstrates mild but diffuse hyperintense appearance of the white matter, mainly located in the neighborhood of the ventricle horns. (C) In sagittal T2-weighted image, there is marked thinning of the entire corpus callosum. (D) Coronal T2-weighted image reveals enlargement of the lateral and third ventricles with atrophy of the bilateral caudate nuclei.](gr2){#fig2}

![Both T1 and fluid-attenuated inversion recovery images demonstrate symmetrical hypointense lesions in basal ganglia.](gr3){#fig3}

![Computed tomography of the proband reveals symmetrical hyperdense lesions resembling calcifications in the globus pallidus.](gr4){#fig4}

###### 

Main features of all the patients described in the literature with *TREM2* mutations presenting without an osseous phenotype

                       [@bib1]                                                                                                                                                                                                                                                                                               [@bib3]                                                                                                                   [@bib2]                                                                                                             Present study                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  -------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- ------------------- ------------ -------------------
  Number of families   1                                                                                                                                                                                                                                                                                                     3                                                                                                                         1                                                                                                                   1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  Geographic origin    Lebanon                                                                                                                                                                                                                                                                                               Turkey                                                                                                                    Colombia                                                                                                            Turkey                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                       Sibling 1                                                                                                                                                                                                                                                                                             Sibling 2                                                                                                                 Sibling 3                                                                                                           Patient 1                                                                                                                    Patient 2                                                                                             Patient 3                                                                                                                                           Sibling 1                                                                                                                                                                                                                                                      Sibling 2   Sibling 3 (index)   Sibling 1    Sibling 2 (index)
  Gender               F                                                                                                                                                                                                                                                                                                     F                                                                                                                         M                                                                                                                   M                                                                                                                            M                                                                                                     M                                                                                                                                                   M                                                                                                                                                                                                                                                              F           F                   F            F
  Diagnosis            Early-onset dementia                                                                                                                                                                                                                                                                                  bvFTD like                                                                                                                bvFTD                                                                                                               bvFTD like                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Age at onset (y)     30--35                                                                                                                                                                                                                                                                                                20                                                                                                                        Late 30s                                                                                                            33                                                                                                                           50                                                                                                    45                                                                                                                                                  47                                                                                                                                                                                                                                                             32          36                               
  Age at death (y)     50                                                                                                                                                                                                                                                                                                    Alive (50)                                                                                                                46                                                                                                                  33                                                                                                                           Alive (50)                                                                                            45                                                                                                                                                  Alive (55)                                                                                                                                                                                                                                                     NA          Alive (48)          Alive (40)   Alive (41)
  Initial symptoms     Forgetfulness and fatigue                                                                                                                                                                                                                                                                             Personality changes with aggressive behavior                                                                              Personality changes with aggressive and perseverative behavior                                                      Generalized T-C seizure                                                                                                      Altered social behavior and oropharyngeal tic in 1 sibling                                            Behavioral changes with nonfluent aphasia                                                                                                           Generalized T-C seizures                                                                                                                                                                                                                                                                                    
  Other symptoms       Neuropsychiatric signsUI and impotence                                                                                                                                                                                                                                                                Generalized T-C seizuresCognitive impairmentOphthalmoplegia with bradykinesia and brisk deep tendon reflexes              Cognitive impairmentBradykinesia, apraxia + postural instability                                                    Personality changes with progressive behavioral problemsBradykinesia + mild postural instabilityVisual hallucinationsUI      New onset of substance useComplex partial seizuresSevere pan-frontal syndrome and cognitive decline   Generalized T-C seizuresBradykinesia + postural instabilityUI                                                                                       Cognitive deterioration + behavioral changes                                                                                                                                                                                                                                                                
  Brain imaging        Diffuse brain and cortical atrophy in the polar region of the temporal lobesCC thinningStenosis of the aqueduct of sylvius + arachnoid cyst in the posterior cranial fossaPeriventricular leucoaraiosisRelative enlargement of perivascular Virchow-Robin spacesNo lenticulopallidal calcifications   Frontal and temporal cortical atrophyCC thinningDiffuse confluent WM abnormalitiesNo calcification of the basal ganglia   Frontal cortical atrophy with marked ventricular enlargementCC thinningConfluent periventricular WM abnormalities   Cortical atrophy predominantly affecting the frontal loesDiffuse confluent WM lesionsNo calcification of the basal ganglia   Asymmetric bifrontal atrophy                                                                          Frontoparietal and temporal cortical atrophyMarked CC thinningDiffuse periventricular and frontal WM lesionsNo calcification of the basal ganglia   Global cortical atrophy mainly in frontal, lateral temporal and parietal cortices and caudate nucleiCC thinningEnlargement of ventricular systemHyperintensity in periventricular, frontal and occipitoparietal WMBilateral calcification in globus pallidus                                                
  Family history       No history of dementia in the parents                                                                                                                                                                                                                                                                 History of dementia, psychotic disorders, and epilepsy in the family                                                      One brother, paternal uncle, and maternal grandfather presented late-onset memory impairment                        No family history of cognitive or behavioral impairment                                                                      One paternal uncle and brother had similar symptoms                                                   No family history of cognitive or behavioral impairment                                                                                                                                                                                                                                                                                                                                                                                                         
  TREM2 mutation       c.40+3delAGG                                                                                                                                                                                                                                                                                          c.97C\>T; p.Q33X                                                                                                          c.197C\>T; p.T66M                                                                                                   c.113A\>G; p.Y38C                                                                                                            c.594G\>A; p.W198X                                                                                    c.\[113A\>G\];\[257A\>T\]; p.\[(Y38C)\];\[(D86V)\]                                                                                                                                                                                                                                                                                                                                                                                                              

Key: bvFTD, behavioral variant frontotemporal dementia; CC, corpus callosum; F, female; M, male; NA, not applicable; T-C, tonic-clonic; UI, urinary incontinence; WM, white matter.
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